Pharmacokinetics-Based DNA-Encoded Library Screening
Pharmacokinetics-Based DNA-Encoded Library Screening
批准号:
10644211
负责人:
Juan Hu
金额:
$12.5万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-01 至 2025-03-31
关键词:
3-DimensionalA549Academic TrainingAddressAlkynesAmino AcidsAreaAzidesBindingBiological AssayBiologyCarboxylic AcidsCareer MobilityCell LineCell Membrane PermeabilityCellsCellular AssayChemicalsClassificationClinicCollaborationsCommunitiesComplexCopperCoupledCyclic PeptidesCysteineDNADataData SetDescriptorDetectionDevelopmentDiagnosticDimensionsDrug KineticsEncapsulatedEngineeringEnvironmentExhibitsFundingFutureGenerationsGoalsGrowthHandHela CellsHumanHydrogen BondingImageIn VitroInstitutionLabelLibrariesLigandsLipidsLiposomesMachine LearningMeasurementMembraneMicrofluidicsModalityModelingMolecularMolecular ConformationPenetrationPeptidesPeriodicityPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPhasePhospholipidsPositioning AttributeProlinePropertyProteinsProteomePublishingRadialReactionResearchResearch PersonnelS phaseScreening ResultSolidSolventsSortingStructureStructure-Activity RelationshipSurfaceTechniquesTechnologyTestingThalidomideTherapeuticTrainingVesicleVisualizationWateracademic preparationassay developmentcareercareer developmentcombinatorialcomputational chemistryconformercycloadditiondesigndrug candidatehigh throughput screeninghigh throughput technologyjob marketmachine learning modelmemberminiaturizemolecular dynamicsmolecular massnext generationnovelnovel diagnosticsnovel therapeuticspre-clinicalpropargylamineprotein protein interactionscreeningskillssmall moleculesmall molecule librariestechnology developmenttool
中文摘要
项目摘要
这个K99/R 00提案寻求通过以下途径扩大可药物化蛋白质靶点的空间:
开发新的分析技术,将指导下一代,非
分子治疗学与诊断学。环肽,其不是药物样的(即,利平斯基-
例如),对于解决不可治疗的目标,特别是蛋白质-蛋白质相互作用(PPI),具有很大的希望。
然而,更大的分子量和更复杂的二级结构导致了不可预测的和几乎不可预测的结果。
总是低的细胞渗透性,显著削弱了它们作为候选药物甚至作为临床前工具的效用
细胞中的化合物。环肽很少会表现出异常高的渗透性。然而,数据不足
存在的目的是揭示渗透的规则,因为细胞渗透的高通量测量
根本不存在在这个建议中,一个高通量的体外渗透试验兼容的DNA编码的
将开发组合文库(DEL)筛选并将其小型化至微流体液滴规模。的
渗透试验将用于筛选DEL以鉴定有效渗透膜的物质
双层。渗透性大环命中物将在基于细胞的渗透测定中进一步验证,该测定还将
在项目中开发。大型筛选数据集将揭示渗透率和渗透率之间的关系。
结构,特别是对于超出5规则(bRo 5)的分子,将使用机器进一步分析
学习利用这些和其他经验推导的大环肽药代动力学性质的模型,
另一方面,我们可能最终能够将这些非Lipinski分子从实验室大规模转移到临床。这项建议
将大大提高PI的职业发展,并推动她朝着成为一名
在一家以研究为重点的机构担任独立调查员。拟议项目提供切割方面的培训-
边缘研究技能,包括基于细胞的检测开发和高内涵成像,DEL设计,合成
和筛选技术的发展,以及机器学习技术。加州大学欧文分校提供了一个理想的
学术培训环境,与世界知名的医学和计算化学专家,
化学生物学和微流体工程。此外,UCI提供了一个智力环境,
鼓励协作与合作,使候选人的成长为科学的一员
社区事实上,PI将参与旨在实现独立性的活动,包括实验室培训,
管理和培训,网络,以及为学术就业市场做准备。总之,
拟议的计划将使PI的科学和职业明智的增长和独立性,进一步定位她
以获得未来的R 01资金。
英文摘要
PROJECT ABSTRACT
This K99/R00 proposal seeks to expand the space of druggable protein targets through the
development of novel analytical technology that will guide the design of next-generation, non-
Lipinski molecular therapeutics and diagnostics. Cyclic peptides, which are not drug-like (i.e., Lipinski-
like), hold great promise for addressing undruggable targets, especially protein-protein interactions (PPIs).
However, the larger molecular mass and more complex secondary structures result in unpredictable and almost
always low cell permeation, significantly blunting their utility as drug candidates and even as preclinical tool
compounds in cells. Rarely, a cyclic peptide will exhibit anomalously high permeation. However, insufficient data
exist to uncover the rules dictating permeation because high-throughput measurements of cell permeation
simply do not exist. In this proposal, a high-throughput in vitro permeation assay compatible with DNA-encoded
combinatorial library (DEL) screening will be developed and miniaturized to the microfluidic droplet scale. The
permeation assay will be applied to screen DELs to identify the species that efficiently permeate membrane
bilayers. The permeable macrocycle hits will be further validated in a cell-based permeation assay that will also
be developed in the project. The large screening data sets will reveal relationships between permeability and
structure, especially for molecules of beyond the Rule of 5 (bRo5), which will be further analyzed using machine
learning. With these and other empirically derived models of macrocyclic peptide pharmacokinetic properties in
hand, we may finally be able to move such non-Lipinski molecules from the lab to the clinic at scale. This proposal
will significantly enhance the PI’s career development and advance her toward her career goal of becoming an
independent investigator at a research-focused institution. The proposed project provides training in cutting-
edge research skills, including cell-based assay development and high-content imaging, DEL design, synthesis
and screening technology development, and machine learning techniques. UC Irvine provides an ideal
environment for academic training, with world-renowned experts in medicinal and computational chemistry,
chemical biology and microfluidics engineering. In addition, UCI provides an intellectual environment that
encourages collaboration and cooperation, enabling the candidate’s growth as a member of the scientific
community. Indeed, the PI will engage in activities designed to achieve independence, including training in lab
management and grantsmanship, networking, and preparation for the academic job market. In summary, the
proposed plan will enable the PI’s scientific and career-wise growth and independence, further positioning her
to attain future R01 funding.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
-
批准号:22007020
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:周志
-
依托单位:
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:周志
-
依托单位:
内蒙古白云鄂博稀土矿区大气可吸入颗粒物对A549细胞毒理研究
-
批准号:81473017
-
项目类别:面上项目
-
资助金额:66.0万元
-
批准年份:2014
-
负责人:孙涓
-
依托单位:
用于识别癌细胞A549的磁共振和荧光双功能探针的研究
-
批准号:21305156
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2013
-
负责人:陈世桢
-
依托单位:
DNA甲基化参与非小细胞肺癌细胞(A549/DDP)顺铂耐药的研究
-
批准号:81101650
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:张有为
-
依托单位:
白藜芦醇诱导人肺癌A549细胞PML蛋白自噬性降解的机制研究
-
批准号:81172089
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:李冠武
-
依托单位:
Id3在肺腺癌中的表达分析及其对A549肺腺癌细胞增殖影响的机制研究
-
批准号:81171652
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:李晓军
-
依托单位:
hTERT启动子调控下CD137L在肺癌A549细胞中的表达及其抑制肿瘤免疫的实验研究
-
批准号:81172140
-
项目类别:面上项目
-
资助金额:64.0万元
-
批准年份:2011
-
负责人:束永前
-
依托单位:
姜黄素调控肺腺癌A549细胞株SP细胞Wnt信号通路的研究
-
批准号:81001578
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2010
-
负责人:李小江
-
依托单位:
PTEN抑制A549肺癌细胞趋电性及调控直流电场对肺癌转移诱导的研究
-
批准号:81000938
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:闫小龙
-
依托单位: